Navigation Links
NOVAVAX to Present at Oppenheimer 20th Annual Healthcare Conference
Date:10/29/2009

ROCKVILLE, Md., Oct. 29 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr. Rahul Singhvi, President and Chief Executive Officer, will be presenting at the Oppenheimer 20th Annual Healthcare Conference. Dr. Singhvi's presentation will take place at 3:20 pm local time on November 3, 2009 at the Waldorf=Astoria, New York, NY. Dr. Singhvi will provide an overview of the company's business strategy and research and development progress. A link to the live presentation can be accessed via the Company website at www.novavax.com under the Investors tab. An archive of the presentation will be available one hour after the event on the Novavax website for 90 days.

About the Oppenheimer 20th Annual Healthcare Conference

The Oppenheimer 20th Annual Healthcare Conference will take place at the Waldorf=Astoria in New York City, November 3-4, 2009. This conference will present a core group of public and private companies who are leaders and pioneers in the pharmaceutical, biotechnology, medical device, healthcare facility, health technology and distribution, provider and service industries. Over 19 years, the Oppenheimer Healthcare Conference has become a highly valuable investor conference in this sector. Through formal company presentations and panels, attendees will gain insight from, and access to, industry leaders.

The Companies participating in this conference will address topical issues such as health reform, Medicare and Medicaid, generic drug regulation, development of new blockbuster pharmaceutical and biotechnology products, product safety and patent issues, cross-border reimportation, Food and Drug Administration policy, managed care, and the current M&A environment.'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Novavax Announces Poster Presentation at the 47th Annual Meeting of the IDSA
2. Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India
3. Novavax Awarded NIH Grant for Respiratory Syncytial Virus (RSV) Vaccine Program
4. Novavax CEO to Present at the World Vaccine Congress 2009, Lyon, France
5. Novavax Announces Board of Director Changes
6. NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine Candidate
7. NOVAVAX Virus-Like Particle Vaccine Protects Against 2009 Pandemic H1N1 Influenza Virus
8. Novavax Reports Second Quarter 2009 Financial Results
9. Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer
10. Novavax Announces Release Date of 2009 Second Quarter, Financial Results and Investor Conference Call
11. Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Physicians Choice Laboratory Services (PCLS) ... which enables healthcare providers to individualize therapeutic treatments ... results, healthcare providers are better able to assess ... minimizing risks for adverse drug reactions and interactions. ... FDA [1] more than 2.2 million adverse drug ...
(Date:10/22/2014)... --  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... and diseases, announced today that the U.S. Patent and ... a composition of matter patent application that covers the ... This is Synthetic Biologics, first allowed patent application directly ... the Company,s extensive C. difficile patent estate. ...
(Date:10/22/2014)... , Oct. 22, 2014 Nuvilex, Inc. ... approximately 400 million people worldwide are living with diabetes, ... people by 2030.  The global market for diabetes treatments ... approximately 330,000 people worldwide died from pancreatic cancer.  Pancreatic ... due to cancer in the United States ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 /PRNewswire/ ... announced today that rare disease expert John C. ... research. Dr. McKew brings more than two decades of ... the National Institutes of Health, Wyeth Research and Genetics ... will lead aTyr,s efforts to expand and translate its ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... 16 Medical and technical experts at Wyle are ... Station. Their efforts will help astronauts cope with effects ... in a future mission to Mars. , "If successful, ... exploration missions and provide us with better insight into ...
... , , SEATTLE, Nov. 16 ... "Company") today announced that the Company,s product candidate PX-866, ... Information, Inc., as one of the Top 10 most ... partnering. , The selection was made by an independent ...
... , LONDON, Nov. 16 The ... field of biomarker research will test the frontiers of biomedical ... day and this rapid development promises excellent growth potential for ... in biomarker validation and assay development, there is a huge ...
Cached Biology Technology:Wyle Personnel Take Part in Important Studies Aboard the International Space Station 2Wyle Personnel Take Part in Important Studies Aboard the International Space Station 3Oncothyreon's PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover 2Oncothyreon's PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover 3Frost & Sullivan Reveals Strategies on Turning Challenges into Opportunities in the European Biomarkers Market 2
(Date:10/19/2014)... access in India over the last 30 years ... emissions growth during that time, according to a ... Climate Change ., "Energy access is fundamental to ... life, including education, communication, and health," says IIASA ... While increased energy access is widely agreed to ...
(Date:10/17/2014)... critical and pertinent for practicing physicians and clinicians given ... The Journal, Disaster Medicine and Public Health Preparedness ... Public Health, to surround the public, medical professionals and ... , On October 17, the journal published ... was prepared by Dr. Eric Toner, internist and emergency ...
(Date:10/16/2014)... the human body. Battles are won, lost or ... this stalemate—known as tumor dormancy—can last up to ... that is poorly understood. , A new ... Torquato, a Professor of Chemistry at Princeton University, ... and the switch to a malignant state. Published ...
Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Modeling tumor dormancy 2
... few things as important on, and especially off, Earth as ... don,t have seconds to spare, which is why development of ... monitor can measure the concentrations of multiple gases within the ... designed the Multi-Gas Monitor to be resistant to shock and ...
... the right shape might be just as important in a ... an important role in the effectiveness of cells grown to ... design new structures that enable cells to "shape up," researchers ... come up with a way to measure, and more importantly, ...
... sound very durable. But the new type of micro-factories invented ... They will actually be placed inside a patient,s body ... will gradually dissolve and disappear in the patient,s urine once ... that Associate Professor of Chemistry Alexander Zelikin, Aarhus University, has ...
Cached Biology News:Rugged, rapid monitor safeguards space crews 2Rugged, rapid monitor safeguards space crews 3Shape-sifting: NIST categorizes bio scaffolds by characteristic cell shapes 2Tiny soft medicine factories 2
Rabbit polyclonal to ErbB 2 (phospho Y1248) ( Abpromise for all tested applications). entrezGeneID: 2064 SwissProtID: P04626...
The Microseal 384 plate positioner ensures precise positioning of Microseal 384-well plates in the x-, y-, and z-dimensions, for accurate automated liquid handling....
... sealing material is suitable for PCR ... down heated lid), especially 384-well formats ... for sample retrieval. Multiple seals can ... Ideal for compound management and high ...
... Nikon's Digital Sight DS-U2 camera controller is ... is specifically designed to interface any of the ... a PC computer through a USB2.0 interface. The ... complicated and cumbersome installation by equipping both hub ...
Biology Products: